Treatment response of CNS high-grade neuroepithelial tumors with MN1 alteration

Lorena Baroni¹, Carlos Rugilo², Fabiana Lubieniecki³, Claudia Sampor⁴, Candela Freytes⁴, Liana Nobre⁵, Jordan Hansford⁶, Vajiranee Malalasekera⁷, Michal Zapotocky⁸, Andrew Dodgshun⁹, Ofelia Cruz Martinez¹⁰, Stefan Rutkowski¹¹, Ulrich Schüller¹², Eric Bouffet⁵, Vijay Ramaswamy⁵, and Daniel Alderete³

May 18, 2020

Abstract

CNS high-grade neuroepithelial tumor with MN1 alteration (CNS HGNET-MN1) is a rare entity recently described. Thirteen CNS HGNET-MN1 patients were identified using genome wide methylation arrays/RT-PCR across 7 institutions and were correlated with treatment and outcome. All patients had surgery (GTR:9/STR:4) as initial management followed by radiotherapy (focal:5/craniospinal:2/CyberKnife:1) and systemic chemotherapy in 3 patients. Seven patients relapsed; 5 local and 2 metastatic despite complete resection and radiotherapy. Three patients died due to their tumor relapse after 24 months despite upfront radiotherapy. Treatment of CNS HGNET-MN1 remains a major challenge with multiple failures, despite aggressive surgical resections and upfront radiotherapy.

Hosted file

 $\label{lem:manuscript MN1 FINAL.} treatment-response-of-cns-high-grade-neuroepithelial-tumors-with-mn1-alteration$

Hosted file

TABLE 1 FINAL 2.doc available at https://authorea.com/users/323134/articles/451987-treatment-response-of-cns-high-grade-neuroepithelial-tumors-with-mn1-alteration

Hosted file

 $^{^{1}}$ SickKids

²Hospital Garrahan

³Hospital de Pediatría Prof. Dr. Juan P. Garrahan

⁴Hospital de Pediatría "Prof Dr JPGarrahan"

⁵Hospital for Sick Children

⁶Royal Children's Hospital

⁷Children Cancer's Centre

⁸Charles University

⁹Christchurch Hospital

¹⁰Hospital Sant Joan de Deu

¹¹University Medical Center Hamburg-Eppendorf

¹²Universitatsklinikum Hamburg Eppendorf Institut fur Neuropathologie

 $\label{thm:com/users/323134/articles/451987-treatment-response-of-cns-high-grade-neuroepithelial-tumors-with-mn1-alteration$

